Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 6/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925918 | 1.00 | TLR8 (0.35) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL9925921 | 1.00 | TLR8 (0.35) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL9924587 | 0.88 | TLR8 (0.35) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL9168808 | 0.87 | APP (0.44) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL19726870 | 0.85 | TLR8 (0.33) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL20725862 | 0.85 | TLR8 (0.33) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL179364 | 0.85 | TLR8 (0.33) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL179360 | 0.85 | TLR8 (0.33) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL179343 | 0.85 | TLR8 (0.33) | TLR8TLR7CDK1CCNB1CCNA2 | |
| SCHEMBL179392 | 0.84 | TLR8 (0.35) | TLR8TLR7CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9527847-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140343057-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8828998-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885TLR7 4114/4885CDK1 88/4885 |
| US-20140343057-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | MYLK2, SSB, MYLK | TLR8 605/4885TLR7 424/4885CDK1 234/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | TLR8 4218/4885TLR7 4273/4885CDK1 69/4885 |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | TLR8 4301/4885TLR7 3414/4885CDK1 298/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | TLR8 4565/4885TLR7 4345/4885CDK1 110/4885 |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | TLR8 4565/4885TLR7 4345/4885CDK1 110/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885TLR7 4114/4885CDK1 88/4885 |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | TLR8 4218/4885TLR7 4273/4885CDK1 69/4885 |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | TLR8 4565/4885TLR7 4345/4885CDK1 110/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885TLR7 4114/4885CDK1 88/4885 |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885TLR7 4114/4885CDK1 88/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | TLR8 3751/4885TLR7 3302/4885CDK1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.